AutomerateX is believed to be a technology firm that specializes in providing automation solutions to streamline business processes and enhance operational efficiency. The company's offerings likely include a suite of software tools designed to automate repetitive tasks, improve data management, and facilitate integration across various platforms.

AutomerateX

Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Automera aims to leverage its unique understanding of autophagy, drug development capabilities, and access to quantum chemistry and generative AI-enabled insights to enhance its drug development programs. Automera’s AUTAC platform has broad potential across cancer and other disease areas, with oncology being the initial lead program. The company was founded by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd. 

Automera

We're thrilled to share that we've just closed a $16 million Series A financing round with some incredible partners on board: Accelerator Life Science Partners, ClavystBio, EDBI Pte Ltd, and Xora Innovation. With this financing we will work to harness the versatile degradation capabilities of autophagy by developing novel autophagy-targeting chimeras for therapeutic applications.
 
Thank you to our investors, partners, and the entire team for their dedication and hard work. Together, we are committed to making a meaningful impact in healthcare.

https://lnkd.in/g3G9NtdF


COM:AUTOMERATX

AutomerateX

Financials Not Available